Trial Search Results

Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management

The purpose of this study is to evaluate and compare the effectiveness of the HeartMate II (HM II) Left Ventricular Assist Device (LVAD) support versus OMM in ambulatory NYHA Class IIIB/IV heart failure patients who are not dependent on intravenous inotropic support and who meet the FDA approved indications for HM II LVAD destination therapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Thoratec Corporation

Stanford Investigator(s):


  • Device: HM II (HeartMate II LVAD)
  • Drug: OMM (Optimal Medical Management)




The following are general criteria; more specific criteria are included in the study

Inclusion Criteria:

   - NYHA Class IIIB/IV (refer to Appendix IV for definitions)

   - Left ventricular ejection fraction (LVEF) ≤ 25%

   - Not currently listed for heart transplantation, and not planned in next 12 months

   - On optimal medical management

   - Limited functional status as demonstrated by 6MWT <300 meters

   - At least:

      - One hospitalization for HF in last 12 months or

      - At least 2 unscheduled emergency room or infusion clinic visits (may include
      intravenous diuretic therapy, etc.) for HF in last 12 months

Exclusion Criteria:

   - Presence of mechanical aortic or mitral valve, including planned conversion to

   - Platelet count < 100,000/mi within 48 prior to enrollment

   - Any inotrope use within 30 days prior to enrollment

   - Inability to perform 6MWT for any reason

   - Any condition, other than heart failure, that could limit survival to less than 2

   - History of cardiac or other organ transplant

   - Existence of any ongoing mechanical circulatory support (including intraaortic balloon
   pump, temporary circulatory support devices, etc.) at the time of enrollment

   - Presence of active, uncontrolled, systemic infection

   - History of an unresolved stroke within 90 days prior to enrollment, or a history of
   cerebral vascular disease with significant (> 80%)extracranial stenosis

   - Contraindication to anticoagulation/antiplatelet therapy

   - CRT or CRT-D within 3 months prior to enrollment

   - Coronary revascularization (e.g. CABG, PCI) within 3 months prior to enrollment

Ages Eligible for Study

18 Years - 85 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Dipanjan Banerjee
Not Recruiting